{
    "body": "What is Contrave prescribed for?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20673995", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22313529", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26679384", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26105116", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25258511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26222044", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26957883", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20509712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26313898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21951371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26648466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19777400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23408728"
    ], 
    "ideal_answer": [
        "Contrave(?) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity", 
        "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity", 
        "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity."
    ], 
    "exact_answer": [
        "Obesity"
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009271", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055553", 
        "http://www.biosemantics.org/jochem#4276121", 
        "http://www.biosemantics.org/jochem#4249647", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016642"
    ], 
    "type": "factoid", 
    "id": "58a32edd60087bc10a000012", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 147, 
            "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 751, 
            "offsetInEndSection": 984, 
            "text": "Assuming that the results of the Contrave phase III clinical program reaffirm the efficacy and safety of the drug combination, this agent could be approved and launched to become a market leader in the anti-obesity therapeutic arena.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 494, 
            "offsetInEndSection": 924, 
            "text": "Current antiobesity medications and pharmacological strategies will be reviewed.Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 271, 
            "offsetInEndSection": 698, 
            "text": "The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants.Men and women aged 18-65 years who had a body-mass index (BMI) of 30-45 kg/m(2) and uncomplicated obesity or BMI 27-45 kg/m(2) with dyslipidaemia or hypertension were eligible for enrolment in this randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 34 sites in the USA.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20673995", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 241, 
            "text": "Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 189, 
            "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 63, 
            "text": "Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20509712", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 97, 
            "text": "Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 114, 
            "text": "Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957883", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 939, 
            "offsetInEndSection": 1110, 
            "text": " The use of synergies of anti-obesity drugs with different mechanisms of action is an effective approach for developing new combined pharmaceutical compositions (Contrave\u00ae", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648466", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 448, 
            "text": "Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave(\u00ae), Mysimba(\u2122)) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of \u2265 30 kg/m(2) (i.e. obese) or a BMI of \u2265 27 kg/m(2) (i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26105116", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 330, 
            "offsetInEndSection": 370, 
            "text": "naltrexone/bupropion (NB32 or Contrave\u00ae)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26222044", 
            "endSection": "abstract"
        }
    ]
}